Will you answer? Since 2019, over 5,000 investors have seized the opportunity to become biotech investors.
🔓 Opportunity Is Knocking. Will You Answer?
Now, you have the unique opportunity to pick up a biotech stock before the open stock market. We are the next disruptive early-stage biotech opportunity in the regenerative medicine sector, developing a novel biologic therapy for osteoarthritis (OA). To date, there are no effective therapies that actually treat the root molecular cause of the disease, and over $180B is spent globally on painkillers and anti-inflammatories that merely mask symptoms. Cytonics’ lead drug candidate, 🧬 CYT-108, is a genetically engineered protein variant of a naturally occurring enzyme that has been proven to reverse the progression of osteoarthritis and restore joint health in preclinical experiments.
CYT-108 binding protease enzymes, halting the degradation of cartilage tissue.
We are gearing up for a first-in-human Phase 1 human clinical trial in early Q2 2024.
A massive milestone and valuation inflection point.
If approved by the FDA, CYT-108 will likely be the first and only disease-modifying treatment for OA, cracking open a $200-300B global market 🌐. Having raised over 💰 $25M to-date from sophisticated investors, equity crowdfunding, a family office, and Synthes (bought by Johnson and Johnson, a 12% shareholder in Cytonics). You have the opportunity to invest in us before we complete Phase 1 and experience an exponential increase in valuation. This is a time sensitive opportunity that won’t last forever.
Together, we are paving the way to a ❤️ healthier and happier future for you, your loved ones, and the world at large 🌍
Ready to become a shareholder? Visit invest.cytonics.com.
This communication may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.
Leave a Reply